drugset / Trial / NCT01769066

Clinical Value of Sequential Gefitinib With Pemetrexed/Platinum for Advanced NSCLC

NCT01769066

Phase 2/3 Completed 117 enrolled Fudan University
RandomizedParallel-groupOpen-labelTreatment

Summary

The aim of this study is to explore the Clinical Value of Sequential Gefitinib With Pemetrexed/Platinum compare with Pemetrexed/Platinum for Advanced NSCLC.

Timeline

Start
2009-12
Primary completion
2014-02
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Gefitinib Small molecule 250 mg Oral
Background CAP Unknown 5 unknown Intravenous
Background DDP Unknown 75 mg/m2 Intravenous
Background Pemetrexed Small molecule 500 mg/m2 Intravenous